Protara Therapeutics, Inc. (TARA) Tops Q2 EPS by 29c

Protara Therapeutics, Inc. (NASDAQ: TARA) reported Q2 EPS of ($0.45), $0.29 better than the analyst estimate of ($0.74).

For earnings history and earnings-related data on Protara Therapeutics, Inc. (TARA) click here.

You May Also Be Interested In

• Canaccord Downgrades York Space Systems (YSS) to Hold, 'Supply chain and contract timing uncertainty'
• EyePoint Inc. (EYPT) PT Lowered to $48 at Laidlaw
• Enovix Corporation (ENVX) PT Lowered to $10 at Cantor Fitzgerald